aimtiaz's  Instablog

Send Message
I have worked with numerous brokers and syndicated publications on various financial topics including Equities, Forex and Global Macro. After earning a degree in International Business, I worked in the management consulting sector for a while. Currently I work as an analyst in a small fund and I... More
My blog:
  • Prosensa's Failure Will Not Justify Buying Sarepta 0 comments
    Oct 7, 2013 6:29 AM | about stocks: RNA, SRPT

    Recently, shares of Prosensa (NASDAQ:RNA) dropped 70% after announcing the negative outcome from its phase III study of an experimental drug, Drisapersen. Meanwhile Sarepta Therapeutics (NASDAQ:SRPT) has seen a significant increase in their market capitalization.

    Comparing the price of Prosensa to its competing company, Sarepta Therapeutics, we find that there seems to be a strong negative correlation between the failure of Prosensa to rise in Sarepta's stock price.

    Find out why it is a bad idea to buy Sarepta based on Prosensa's failure.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: RNA, SRPT
Back To aimtiaz's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.